Efficacy of Generic Highly Active Antiretroviral Therapy in HIV-1 Infected Individuals in Nigeria

REFERENCES

• UNAIDS and WHO. Guidance Modules on Antiretroviral Treatments: Module 5, Laboratory Requirements for the Safe and Effective Use of Antiretrovirals, 1998 WHO/AIDS/98.1 UNAIDS/98.7.
   Google Scholar
• John, G.B.; Joel, E.G. Laboratory Test In 2001-2002 Medical Management of HIV Infection. Johns Hopkins University, Division of Infectious Diseases, 200; pp. 5–30.
   Google Scholar
• Gunnel, B.; Eligius, L. Monitoring Immune Function. In AIDS in Africa. 2nd ed.; Essex, M.; Mboup, S.; Kanki, P.J.; Marlink, R.G.; Tlou, S.D., Eds.; Kluwer Academic/ Plenum Publisher: New York, 2002; pp. 185–199.
   Google Scholar
• Pachl, C.; Todd, J.A.; Kern, D.G.; Sheridan P.J.; Fong, S.J.; Stempien, M.; Hoo, B.; Besemer, D.; Yeghiazarian, T.; Irvine, B. Rapid and Precise Quantification of HIV-1 RNA in Plasma using a Branched DNA Signal Amplification Assay. J. Acq. Immun. Defic. Syn. Hum. Retrovirol. 1995, 8(5), 446–454.
   PubMedGoogle Scholar
• Mellors, J.W.; Kingsley, L.A.; Rinaldo, C.R., Jr.; Todd, J.A.; Hoo, B.S.; Kokka, R.P.; Gupta, P. Quantitation of HIV-1 RNA in Plasma Predicts Outcome after Seroconversion. Ann. Intern. Med. 1995, 122, 573–579.
   PubMed Web of Science ®Google Scholar
• Mellors, J.W.; Rinaldo, C.R., Jr.; Gupta, P.; White, R.M.; Todd, J.A.; Kingsley, L.A. Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma. Science 1996, 272, 1167–1170.
   PubMed Web of Science ®Google Scholar
• Mellors, J.W.; Muñoz, A.; Giorgi, J.V.; Margolick, J.B.; Tassoni, C.J.; Gupta, P.; Kingsley, L.A.; Todd, J.A.; Saah, A.J.; Detels, R.; Phair, J.P.; Rinaldo, C. R., Jr. Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection. Ann. Intern. Med. 1997, 126, 946–954.
   PubMed Web of Science ®Google Scholar
• Stein, D.S.; Lyles, R.H.; Graham, N.M; Tassoni C.J.; Margolick, J.B.; Phair, J.P.; Rinaldo, C.; Detels, Saah A.; Bilello J. Predicting Clinical Progression or Death in Subjects with Early-Stage Human Immunodeficiency Virus (HIV) Infection: A Comparative Analysis of Quantification of HIV RNA, Soluble Tumor Necrosis Factor Type II Receptors, Neopterin, and Beta2-microglobulin. Multicenter AIDS Cohort Study. J. Infect. Dis. 1997, 176(5), 1161–1167.
   PubMed Web of Science ®Google Scholar
• Notermans, D.W.; Goudsmit, J.; Danner, S.A.; de Wolf, F.; Perelson, A.S.; Mittler, J. Rate of HIV-1 Decline Following Antiretroviral Therapy is Related to Viral Load at Baseline and Drug Regimen. AIDS 1998, 12(12), 1483–1490.
   PubMed Web of Science ®Google Scholar
• Signore, A.; Cugini, P.; Letizia, C.; Lucia, P.; Murano, G.; Pozzilli, P. Study of the Diurnal Variation of Human Lymphocyte Subsets. J. Clin. Lab. Immunol. 1985, 17, 25–28.
   PubMedGoogle Scholar
• Denny, T.; Yogev, R.; Gelman, R.; Skuza, C.; Oleske, J.; Chadwick, E.; Cheng, S-C.; Connor, E. Lymphocyte Subsets in Healthy Children During the First 5 Years of Life. J. Amer. Med. Assoc. 1992, 267, 1484–1488.
   PubMed Web of Science ®Google Scholar
• Tugume, S.B.; Piwowar, E.M.; Lutalo, T.; Mugyeni, P.N.; Grant, R.M.; Mangeni, F.W.; Pattishall, K.; Katongole-Mbidde, E. Haematological Reference Ranges among Healthy Ugandans. Clin. Diagn. Lab. Immunol. 1995, 2, 233–235.
   PubMedGoogle Scholar
• Maini, M.K.; Gilson, R.J.; Chavda, N.; Gill, S.; Fakoya, A.; Ross, E.J.; Phillips, A.N.; Weller, I.V. Reference Ranges and Sources of Variability of CD4 Counts in HIV-Seronegative Women and Men. Genitour. Med. 1996, 72, 27–31.
   PubMedGoogle Scholar
• Lisse, I.M.; Aaby, P.; Whittle, H.; Jensen, H.; Engelmann, M.; Christensen, L.B. T Lymphocyte Subsets in West African Children: Impact of Age, Sex and Season. J. Pediatr. 1997, 130, 77–85.
   PubMed Web of Science ®Google Scholar
• Zekeng, L.; Sadjo, A.; Meli, J.; Kaptue, L.; Ngole, E.M.; Hess, G.; Babiel, R. T Lymphocyte Subset Values among Healthy Cameroonians. J. Acq. Immun. Defic. Synd. Hum. Retrovirol. 1997, 14, 82–83.
   PubMedGoogle Scholar
• Kanki, P.J.; Indu, M. Monitoring Viral Load. In AIDS in Africa. 2nd ed. Essex, M.; Mboup, S.; Kanki, P.J.; Marlink, R.G.; Tlou, S.D., Eds.; Kluwer Academic/Plenum Publisher: New York; 2002; pp. 173–185.
   Google Scholar
• Olaleye, D.O. The Fingerprints of a Monster: Message from the Dead to the Living. Inaugural Lecture, Ibadan University Printery, U.I. Ventures Limited, August 2003; p. 44.
   Google Scholar
• Ojesina, A.I.; Sankalé, J.L.; Odaibo, G.; Langevin, S.;, Meloni, S.T.; Sarr, A.D.; Olaleye, D.; Kanki, P.J. Subtype-Specific Patterns in HIV Type 1 RSeverse Transcriptase and Protease In Oyo State, Nigeria: Implications for Drug Resistance and Host Response. AIDS Res. Hum. Retrovir. 2006, 22(8), 770–9.
   PubMed Web of Science ®Google Scholar
• Sankalé, J.L.; Langevin, S.; Odaibo, G.; Meloni, S.T.; Ojesina, A.I.; Olaleye, D.; Kanki, P. The Complexity of Circulating HIV Type 1 Strains in Oyo state, Nigeria. AIDS Res. Hum. Retrovir. 2007, 23(8), 1020–1025.
   PubMed Web of Science ®Google Scholar
• Olaleye, O.D.; Sheng, Z.; Howard, T.; Rasheed, S. Biological Characterization of a New Subtype A Variant of Human Immunodeficiency Virus Type 1 from Nigeria. Biochemistry 1995, 5, 51–60.
   Google Scholar
• Agwale, S.M.; Zeh, C.; Robbins, K.E.; Odama, L.; Saekhou, A.; Edubio, A.; Njoku, M.; Sani-Gwarzo, N.; Gboun, M.S.; Gao, F.; Reitz, M.; Hone, D.; Pieniazek, D.; Wambebe, C.; Kalish, M.L. Molecular Surveillance of HIV-1 Field trains in Nigeria in Preparation for Vaccine Trials. Vaccine 2002, 1520(16), 2131–2139.
   Web of Science ®Google Scholar
• Holmes, C.B.; Coggin, W.; Jamieson, D.; Mihm, H.; Granich, R.; Savio, P.; Hope, M.; Ryan, C.; Moloney, M.; Goosby, E.P.; Dybul, M. Use of Generic Antiretroviral Agents and Cost Savings in PEPFAR Treatment Programs. JAMA 2010, 304(3), 313–320.
   PubMed Web of Science ®Google Scholar
• UNAIDS and WHO. 2007 AIDS Epidemic Updates UNAIDS/07.27E/JC1322E, 2007.
   Google Scholar
• UNAIDS and WHO. 2007 Sub-Saharan Africa AIDS Epidemic Update. Regional Summary UNAIDS/08.08E/JC1526E, 2007.
   Google Scholar
• Kaufmann, G.R.; Perrin, L.; Pantaleo, G.; Opravil, M.; Furrer, H.; Telenti, A.; Hirschel, B.; Ledergerber, B.; Vernazza, P.; Bernasconi, E.; Rickenbach, M.; Egger, M.; Battegay, M. CD4 T Lymphocyte Recovery in Individuals with Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 Years: The Swiss HIV Cohort Study Group. Arch. Inter. Med. 2003, 163, 2187–2195.
   PubMed Web of Science ®Google Scholar
• Mulu, A.; Liebert, U.G.; Maier, M. Virological Efficacy and Immunological Recovery among Ethiopian HIV-1 Infected Adults and Children. BMC Infect. Dis. 2014, 14, 28.
   PubMed Web of Science ®Google Scholar
• Autran, B.; Carcelain, G.; Li, T.S.; Blanc, C.; Mathez, D.; Tubiana, R.; Katlama, C.; Debré, P.; Leibowitch, J. Positive Effects of Combined Antiretroviral Therapy on CD4+ T Cell Homeostasis and Function in Advanced HIV Disease. Science 1997, 277(5322), 112–116.
   PubMed Web of Science ®Google Scholar
• Gea-Banacloche, J.C.; Clifford Lane, H. Immune Reconstitution in HIV Infection AIDS. 1999, 13 Suppl A, S25–S38
   Google Scholar
• Plana, M.; García, F.; Gallart, T.; Tortajada, C.; Soriano, A.; Palou, E.; Maleno, M.J.; Barceló, J.J.; Vidal, C.; Cruceta, A.; Miró, J.M.; Gatell, J.M. Immunological Benefits of Antiretroviral Therapy in Very Early Stages of Asymptomatic Chronic HIV-1 Infection. AIDS 2000, 14, 1921–1933.
   PubMed Web of Science ®Google Scholar
• Saag, M.S.; Holodniy, M.; Kuritzkes, D.R.; O’Brien, W.A.; Coombs, R.; Poschef, M.E.; Jacobsen, D.M.; Shaw, G.M.; Richman, D.D.; Volberding, P.A. HIV Viral Load Markers in Clinical Practice. Nat. Med. 1996, 2(6), 625–629.
   PubMed Web of Science ®Google Scholar
• O’Brien, T.R.; Rosenberg, P.S.; Yellin, F.; Goedert, J.J. Longitudinal HIV-1 RNA Levels in a Cohort of Homosexual Men. J. Acq. Imm. Defic. Syndr. 1998, 18(2), 155–161.
   Web of Science ®Google Scholar
• Moore, R.D.; Keruly, J.C. CD4+ Cell Count 6 Years after Commencement of Highly Active Antiretroviral Therapy in Persons with Sustained Virologic Suppression. Clin. Infect. Dis. 2007, 1, 44(3), 441–446.
   PubMed Web of Science ®Google Scholar
• Lavreys, L.; Baeten, J.M.; Chohan, V.; McClelland, R.S.; Hassan, W.M.; Richardson, B.A.; Mandaliya, K.; Ndinya-Achola, J.O.; Overbaugh, J. Higher Set Point Plasma Viral Load and More-Severe Acute HIV Type 1 (HIV-1) Illness Predict Mortality among High-Risk HIV-1 Infected African Women. Clin. Infect. Dis. 2006, 42, 1333–1339.
   PubMed Web of Science ®Google Scholar
• Hammond, R.; Harry, T.C. Efficacy of Antiretroviral Therapy in Africa: Effect on Immunological and Virological Outcome Measures – A Meta-Analysis. Int. J. STD AIDS 2008, 19(Suppl 5), 291–296.
   Web of Science ®Google Scholar
• Aiuti, F.; Mezzaroma, I. Failure to Reconstitute CD4+ T Cells Despite Suppression of HIV Replication under HAART. AIDS Rev. 2006, 8(Suppl 2), 88–97.
   Web of Science ®Google Scholar
• Le Moing, V.; Chêne, G.; Carrieri, M.P.; Alioum, A.; Brun-Vézinet, F.; Piroth, L.; Cassuto, J.P.; Moatti, J.P.; Raffi, F.; Leport, C.; and the Aproco Study Group. Predictors of Virological Rebound in HIV-1 Infected Patients Initiating a Protease-Inhibitor Containing Regimen. AIDS 2002, 16, 21–29.
   PubMed Web of Science ®Google Scholar
• Phillips, A.N.; Staszewski, S.; Lampe, F.; Yuole, M.S.; Klauke, S.; Bickel, M.; Sabin, C.A.; Doerr, H.W.; Johnson, M.A.; Loveday, C.; Miller, V. Human Immunodeficiency Virus Rebound after Suppression to ≤400 copies/ml during Initial Highly Active Antiretroviral Regimens, According to Prior Nucleoside Experience and Duration of Suppression. J. Infect. Dis. 2002, 186, 1086–1091.
   PubMed Web of Science ®Google Scholar
• Mocroft, A.; Ruiz, L.; Reiss, P.; Ledergerber, B.; Katlama, C.; Lazzarin, A.; Goebel, F.D.; Phillips, A.N.; Clotet, B.; Lundgren, J.D. Virological Rebound after Suppression on Highly Active Antiretroviral Therapy. AIDS 2003, 17(Suppl 12), 1741–1751.
   PubMed Web of Science ®Google Scholar
• Deeks, S.G.; Hecht, F.M.; Swanson, M.; Elbeik, T.; Loftus, R.; Cohen, P.T.; Grant, R.M. HIV RNA and CD4 Cell Count Response to Protease Inhibitor Therapy in an Urban AIDS Clinic: Response to Both Initial and Salvage Therapy. AIDS 1999, 13(Suppl 6), F35–43.
   Web of Science ®Google Scholar
• Ledergerber, B.E.; Egger, M.; Opravil, M.; Telenti, A.; Hirschel, B.; Battegay, M.; Vernazza, P.; Sudre, P.; Flepp, M.; Furrer, H.; Francioli, P.; Weber, R. Clinical Progression and Virological Failure on Highly Active Antiretroviral Therapy in HIV-1 Patients: A Prospective Cohort Study. Lancet 1999, 353, 863–868.
   PubMed Web of Science ®Google Scholar
• Lucas, G.M.; Chaisson, R.E.; Moore, R.D. Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virological Failure and Adverse Drug Reactions. Ann. Intern. Med. 1999, 131, 81–87.
   PubMed Web of Science ®Google Scholar
• Mocroft, A.; Devereux, H.; Kinloch-de-Loes, S.; Wilson, D.; Madge, S.; Youle, M.; Tyrer, M.; Loveday, C.; Phillips, A.N.; Johnson, M.A.; Royal Free Ctr. HIV Med. Immunological, Virological and Clinical Response to Highly Active Antiretroviral Therapy Treatment Regimens in a Complete Clinic Population. AIDS 2000, 14( Suppl. 11), 1545–1552.
   PubMed Web of Science ®Google Scholar
• Paredes, R.; Mocroft, A.; Kirk, O.; Lazzarin, A.; Barton, E.S.; van Lunzen, J.; Katzenstein, T.L.; Antunes, F.; Lundgren, J.D.; Clotet, B. Predictors of Virological Success and Ensuing Failure in HIV-Positive Patients Starting Highly Active Antiretroviral Therapy. Arch. Intern. Med. 2000, 160, 1123–1132.
   PubMed Web of Science ®Google Scholar
• British HIV Association Writing Committee (BHAWC). British HIV Association (BHIVA) Guidelines for the Treatment of HIV-Infected Adults with Antiretroviral Therapy. HIV Med. 2001, 2, 276–313.
   PubMedGoogle Scholar
• Yeni, P.G.; Hammer, S.M.; Carpenter, C.C.J.; Cooper, D.A.; Fischl, M.A.; Gatell, J.M.; Gazzard, B.G.; Hirsch, M.S.; Jacobsen, D.M.; Katzenstein, D.A.; Montaner, J.S.; Richman, D.D.; Saag, M.S.; Schechter, M.; Schooley, R.T.; Thompson, M.A.; Vella, S.; Volberding, P.A. Antiretroviral Treatment for Adult HIV Infection in 2002: Updated Recommendations of the International AIDS Society - USA panel. JAMA 2002, 288, 222–235
   Web of Science ®Google Scholar
• Weidle, P.J.; Malamba, S.; Mwebaze, R.; Sozi, C.; Rukundo, G.; Downing, R.; Hanson, D.; Ochola, D.; Mugyenyi, P.; Mermin, J.; Samb, B.; Lackritz, E. Assessment of a Pilot Antiretroviral Drug Therapy Program in Uganda: Patients’ Response, Survival, and Drug Resistance. Lancet 2002, 360, 34–40.
   PubMed Web of Science ®Google Scholar
• Nakanjako, D.; Kyabayinze, D.J.; Mayanja-Kizza, H.; Katabira, E.; Kamya, M.R. Eligibility for HIV/AIDS Treatment among Adults in a Medical Emergency Setting at an Urban Hospital in Uganda. Afr. Health Sci. 2007, 7, 124–128.
   PubMedGoogle Scholar
• Nakanjako, D.; Kiragga, A.; Ibrahim, F.; Castelnuovo, B.; Kamya, M.R.; Easterbrook, P.J. Sub-Optimal CD4 Reconstitution Despite Viral Suppression in an Urban Cohort on Antiretroviral Therapy (ART) in Sub-Saharan Africa: Frequency and Clinical Significance. AIDS Res. Ther. 2008, 5, 23.
   PubMedGoogle Scholar
• Sterling, T.R.; Lyles, C.M.; Vlahov, D.; Astemborski, J.; Margolick, J.B.; Quinn, T.C. Sex Differences in Longitudinal Human Immunodeficiency Virus Type 1 RNA Levels among Seroconverters. J. Infect. Dis. 1999, 180(3), 666–672.
   PubMed Web of Science ®Google Scholar
• Rezza, G.; Lepri, A.C.; d’Arminio Monforte, A; Pezzotti, P.; Castelli, F.; Dianzani, F.; Lazzarin, A.; De Luca, A.; Arlotti, M.; Leoncini, F.; Manconi, Paolo E.; Rizzardini, G.; Minoli, L.; Poggio, A.; Ippolito, G.; Phillips, A.N.; Moroni, M.; for the I.CO.N.A. Study Group. Plasma Viral Load Concentrations in Women and Men from Different Exposure Categories and with Known Duration of HIV Infection. J. Acq. Immun. Defic. Syndr. 2000, 25(1), 56–62.
   PubMed Web of Science ®Google Scholar